keyword
MENU ▼
Read by QxMD icon Read
search

Dpp 4 inhibitors

keyword
https://www.readbyqxmd.com/read/29213240/dipeptidyl-peptidase-4-inhibitors-use-and-relative-risk-of-ischemic-cerebrovascular-disease-in-type-2-diabetic-patients-in-a-case-control-study
#1
Shih-Wei Lai, Kuan-Fu Liao, Cheng-Li Lin, Hsien-Feng Lin
Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan. This study aimed to investigate the association between DPP-4 inhibitors use and the first episode of ischemic cerebrovascular disease. Methods: We designed a case-control study using the database of the Taiwan National Health Insurance Program. There were 1999 type 2 diabetic subjects aged 20-84 years with the first episode of ischemic cerebrovascular disease from 2000 to 2013 as the cases, and 7996 sex- and age-matched, randomly selected type 2 diabetic subjects aged 20-84 years without any type of cerebrovascular diseases as the matched controls...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29208515/effectiveness-of-sitagliptin-in-a-patient-with-late-dumping-syndrome-after-total-gastrectomy
#2
Kotomi Kurihara, Anna Tamai, Yoko Yoshida, Yosuke Yakushiji, Hiroki Ueno, Mariko Fukumoto, Masayuki Hosoi
An 83-year-old man developed hypoglycemia after undergoing total gastrectomy for gastric cancer in 200X-4. The patient was admitted to our hospital in May 200X and placed on continuous glucose monitoring (CGM). Glycemic excursions were examined while on 3-meal/day (1700kcal) and 6-meal/day (1800kcal) diets. Oxyhyperglycemia followed about 2h later by a sudden drop in glucose levels was seen with both regimens. These findings were consistent with late dumping syndrome. CGM was continued, oral miglitol at 150mg/day or sitagliptin at 50mg/day was started, and glycemic excursions were compared...
November 29, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/29206832/the-effects-of-dipeptidyl-peptidase-4-inhibitors-on-bone-fracture-among-patients-with-type-2-diabetes-mellitus-a-network-meta-analysis-of-randomized-controlled-trials
#3
Jun Yang, Chao Huang, Shanshan Wu, Yang Xu, Ting Cai, Sanbao Chai, Zhirong Yang, Feng Sun, Siyan Zhan
AIM: The association between dipeptidyl peptidase-4 inhibitors (DPP-4is), a class of anti-diabetes, and bone fracture in patients with type 2 diabetes mellitus (T2DM) is unknown. This meta-analysis aimed to systematically evaluate the effects of DPP-4is on bone fracture in T2DM patients. METHODS: We searched the Cochrane Library, Embase, Medline and ClinicalTrials.gov from inception through April 28th, 2016 to identify randomized controlled trials (RCTs) that compared DPP-4is with placebo or other anti-diabetes in T2DM patients...
2017: PloS One
https://www.readbyqxmd.com/read/29206336/claims-based-studies-of-oral-glucose-lowering-medications-can-achieve-balance-in-critical-clinical-parameters-only-observed-in-electronic-health-records
#4
E Patorno, C Gopalakrishnan, J M Franklin, K G Brodovicz, E Masso-Gonzalez, D B Bartels, J Liu, S Schneeweiss
BACKGROUND: Healthcare claims databases can provide information on the effects of type 2 diabetes (T2DM) medications as used in routine care, but often do not contain data on important clinical characteristics, which may be captured in electronic health records (EHR). OBJECTIVES: To evaluate the extent to which balance in unmeasured patient characteristics was achieved in claims data, by comparing against more detailed information from linked EHR data. METHODS: Within a large US commercial insurance database and using a cohort design, we identified T2DM patients initiating linagliptin or a comparator agent within class (i...
December 5, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29203362/hla-dqb1-03-01-as-a-biomarker-for-genetic-susceptibility-to-bullous-pemphigoid-induced-by-dpp-4-inhibitors
#5
Hideyuki Ujiie, Ken Muramatsu, Taisei Mushiroda, Takeshi Ozeki, Hideaki Miyoshi, Hiroaki Iwata, Akinobu Nakamura, Hiroshi Nomoto, Kyu Yong Cho, Norihiro Sato, Machiko Nishimura, Takamasa Ito, Kentaro Izumi, Wataru Nishie, Hiroshi Shimizu
No abstract text is available yet for this article.
December 1, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29195509/dpp-4-inhibition-with-linagliptin-ameliorates-the-progression-of-premature-aging-in-klotho-mice
#6
Yu Hasegawa, Kenyu Hayashi, Yushin Takemoto, Cao Cheng, Koki Takane, Bowen Lin, Yoshihiro Komohara, Shokei Kim-Mitsuyama
BACKGROUND: The potential of anti-aging effect of DPP-4 inhibitors is unknown. This study was performed to determine whether linagliptin, a DPP-4 inhibitor, could protect against premature aging in klotho-/- mice. METHODS: Klotho-/- mice exhibit multiple phenotypes resembling human premature aging, including extremely shortened life span, cognitive impairment, hippocampal neurodegeneration, hair loss, muscle atrophy, hypoglycemia, etc. To investigate the effect of linagliptin on these aging-related phenotypes, male klotho-/- mice were divided into two groups: (1) control group fed the standard diet, and (2) linagliptin group fed the standard diet containing linagliptin...
December 1, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29187821/renoprotective-effect-of-dipeptidyl-peptidase-4-inhibitors-in-patients-with-type-2-diabetes-mellitus
#7
Hiroki Esaki, Tomoya Tachi, Chitoshi Goto, Ikuto Sugita, Yuta Kanematsu, Aki Yoshida, Kosuke Saito, Yoshihiro Noguchi, Yuki Ohno, Satoshi Aoyama, Masahiro Yasuda, Takashi Mizui, Masumi Yamamura, Hitomi Teramachi
Diabetic nephropathy is one of three major complications of diabetes mellitus, often leading to chronic renal failure requiring dialysis. Recently developed dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit renoprotective effects in addition to antihyperglycemic effects. In this study, we retrospectively investigated temporal changes in the renal function index of patients with type 2 diabetes mellitus (DM) and examined the influence of DPP-4 inhibitors on renal function. Patients with type 2 DM (>18 years old) prescribed hypoglycemic agents at Gifu Municipal Hospital for ≥3 months between March 2010 and April 2014 were included in the study...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29174215/choosing-dipeptidyl-peptidase-4-inhibitors-sodium-glucose-cotransporter-2-inhibitors-or-both-as-add-ons-to-metformin-patient-baseline-characteristics-are-crucial
#8
Ronald M Goldenberg
PURPOSE: Type 2 diabetes remains a poorly managed disease, with only about half of individuals with type 2 diabetes meeting guideline-recommended glycosylated hemoglobin (HbA1C) targets. A major proportion of those who have not met HbA1C goals have an HbA1C <8.0% to 8.5%. In practice, it is quite common to have to decide between dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) as add-ons to metformin to help these individuals meet their HbA1C goals...
November 22, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29172255/relationship-between-deterioration-of-hba1c-lowering-effects-in-dpp-4-inhibitor-monotherapy-and-dietary-habits-retrospective-analysis-of-japanese-individuals-with-type-2-diabetes
#9
Hitoshi Kuwata, Saki Okamoto, Yusuke Seino, Kenta Murotani, Hisato Tatsuoka, Ryota Usui, Yoshiyuki Hamamoto, Takeshi Kurose, Yutaka Seino, Daisuke Yabe
This study was designed to assess possible relationships between deterioration of the HbA1c-lowering effects in dipeptidyl peptidase-4 inhibitor (DPP4i) monotherapy and macronutrient intake among individuals with type 2 diabetes (T2D). T2D individuals who began and continued DPP4i monotherapy without any prescription change for 1 year were retrospectively stratified into two groups: patients who maintained their HbA1c levels during the 0.5- to 1-year period after DPP4i initiation [Group A, ΔHbA1c (1-0.5 year)<0...
November 24, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29171139/randomized-double-blind-placebo-controlled-dose-finding-study-of-the-dipeptidyl-peptidase-4-inhibitor-linagliptin-in-pediatric-patients-with-type-2-diabetes
#10
William V Tamborlane, Lori Mb Laffel, Jacques Weill, Maud Gordat, Dietmar Neubacher, Silke Retlich, Willem Hettema, Cornelia E Hoesl, Stefan Kaspers, Jan Marquard
OBJECTIVE: To identify the dose of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in pediatric patients with type 2 diabetes (T2D). METHODS: Double-blind, randomized, controlled parallel group study comparing linagliptin 1 and 5 mg once daily, with placebo in 39 patients with T2D aged 10 to below 18 years. The primary efficacy endpoint was the change from baseline in glycated hemoglobin (HbA1c) after 12 weeks of treatment. The key pharmacodynamic endpoint was DPP-4 inhibition during steady-state...
November 24, 2017: Pediatric Diabetes
https://www.readbyqxmd.com/read/29169334/prevalence-and-treatment-of-diabetes-mellitus-and-hypertension-among-older-adults-with-intellectual-disability-in-comparison-with-the-general-population
#11
Anna Axmon, Gerd Ahlström, Peter Höglund
BACKGROUND: Diabetes mellitus and hypertension are risk factors for cardiovascular disease, which is the most common cause of death in the world. People with intellectual disability (ID) have been reported to have high rates of both these disorders. The aim of this study was to describe and compare prevalence ratios of diabetes mellitus and hypertension between older adults with ID and their age peers in the general population, and to describe and compare treatment patterns in these two groups...
November 23, 2017: BMC Geriatrics
https://www.readbyqxmd.com/read/29163166/saxagliptin-attenuates-albuminuria-by-inhibiting-podocyte-epithelial-to-mesenchymal-transition-via-sdf-1%C3%AE-in-diabetic-nephropathy
#12
Yun-Peng Chang, Bei Sun, Zhe Han, Fei Han, Shao-Lan Hu, Xiao-Yu Li, Mei Xue, Yang Yang, Li Chen, Chun-Jun Li, Li-Ming Chen
The dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin has been found to reduce progressive albuminuria, but the exact mechanism of inhibition is unclear. Podocyte epithelial-to-mesenchymal transition (EMT) has emerged as a potential pathway leading to proteinuria in diabetic nephropathy (DN). Stromal cell-derived factor-1α (SDF-1α), one of the substrates of DPP-4, can activate the protein kinase A pathway and subsequently inhibit its downstream effector, transforming growth factor-β1 (TGF-β1), which induces podocyte EMT...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29148282/macrocarpal-c-isolated-from-eucalyptus-globulus-inhibits-dipeptidyl-peptidase-4-in-an-aggregated-form
#13
Eisuke Kato, Kazuhiro Kawakami, Jun Kawabata
Dipeptidyl peptidase 4 (DPP-4) inhibitors are used for the treatment of type-2 diabetes mellitus. Various synthetic inhibitors have been developed to date, and plants containing natural DPP-4 inhibitors have also been identified. Here, 13 plant samples were tested for their DPP-4 inhibitory activity. Macrocarpals A-C were isolated from Eucalyptus globulus through activity-guided fractionation and shown to be DPP-4 inhibitors. Of these, macrocarpal C showed the highest inhibitory activity, demonstrating an inhibition curve characterised by a pronounced increase in activity within a narrow concentration range...
December 2018: Journal of Enzyme Inhibition and Medicinal Chemistry
https://www.readbyqxmd.com/read/29146035/renal-outcomes-with-dipeptidyl-peptidase-4-inhibitors
#14
REVIEW
A J Scheen, P Delanaye
Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular filtration rates (eGFRs) from observational studies and clinical trials, and renal events (including kidney failure requiring renal replacement therapy) in recent large prospective cardiovascular outcome trials...
November 13, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29132091/effect-of-anti-diabetic-drugs-on-bone-metabolism-evidence-from-preclinical-and-clinical-studies
#15
REVIEW
Mohammad Adil, Rashid Ali Khan, Abul Kalam, Shiva Kumar Venkata, Amit Dattatraya Kandhare, Pinaki Ghosh, Manju Sharma
Diabetes mellitus is associated with abnormal bone health and an increased risk of fracture even though patients have normal or higher BMD. The mechanisms behind diabetes mellitus- induced various skeletal disorders remain unclear. Anti-diabetic drugs may have negative or positive impact on bone metabolism. For instance, thiazolidinediones increases the bone loss and risk of fracture possibly through PPARγ activation in bone marrow cells and hamper osteoblastogenesis via decreasing Runx2 transcription factor, IGF-1 and Wnt signalling pathways...
May 25, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29113797/caveolin-1-a-binding-protein-of-cd26-is-essential-for-the-anti-inflammatory-effects-of-dipeptidyl-peptidase-4-inhibitors-on-human-and-mouse-macrophages
#16
Munenori Hiromura, Kyoko Nohtomi, Yusaku Mori, Hideo Kataoka, Marika Sugano, Kei Ohnuma, Hirotaka Kuwata, Tsutomu Hirano
We previously reported that inhibition of dipeptidyl peptidase (DPP)-4, the catalytic site of CD26, prevents atherosclerosis in animal models through suppression of inflammation; however, the underlying molecular mechanisms have not been fully elucidated. Caveolin-1 (Cav-1), a major structural protein of caveolae located on the surface of the cellular membrane, has been reported to modulate inflammatory responses by binding to CD26 in T cells. In this study, we investigated the role of Cav-1 in the suppression of inflammation mediated by the DPP-4 inhibitor, teneligliptin, using mouse and human macrophages...
November 4, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29113790/the-persistent-inhibitory-properties-of-saxagliptin-on-renal-dipeptidyl-peptidase-4-studies-with-hk-2-cells-in%C3%A2-vitro-and-normal-rats-in%C3%A2-vivo
#17
Masako Uchii, Mariko Sakai, Yuhei Hotta, Satoshi Saeki, Naoya Kimoto, Akinori Hamaguchi, Tetsuya Kitayama, Shunji Kunori
Saxagliptin, a potent and selective DPP-4 inhibitor, exhibits a slow dissociation from DPP-4. We investigated the sustained effects of saxagliptin on renal DPP-4 activity in a washout study using renal tubular (HK-2) cells, and in a pharmacodynamic study using normal rats. In HK-2 cells, the inhibitory potency of saxagliptin on DPP-4 activity persisted after washout, while that of sitagliptin was clearly reduced. In normal rats, a single treatment of saxagliptin or sitagliptin inhibited the plasma DPP-4 activity to similar levels...
October 23, 2017: Journal of Pharmacological Sciences
https://www.readbyqxmd.com/read/29110647/a-randomized-placebo-controlled-clinical-trial-evaluating-the-safety-and-efficacy-of-the-once-weekly-dpp-4-inhibitor-omarigliptin-in-patients-with-type-2-diabetes-mellitus-inadequately-controlled-by-glimepiride-and-metformin
#18
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A O'Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D Kaufman, Samuel S Engel, Eseng Lai
BACKGROUND: Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly dipeptidyl peptidase-4 inhibitor. The purpose of this trial was to assess the efficacy and safety of adding omarigliptin to the treatment regimen of patients with T2D inadequately controlled by dual therapy with metformin and glimepiride. METHODS: Patients with T2D and HbA1c ≥7...
November 6, 2017: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29109662/budget-impact-of-introducing-linagliptin-into-bosnia-and-herzegovina-health-insurance-drug-reimbursement-list-in-2016-2018
#19
Tarik Catic, Lana Lekic, Vlad Zah, Vedad Tabakovic
Introduction: Diabetes is reaching epidemiological scales worldwide. Beside health implications diabetes bears significant financial impact on health systems. Different treatment options aiming to prevent diabetes complications are available. Dipeptidyl-peptidase-IV (DPP-4) inhibitors like linagliptin are usually add-on therapy to metformin in order to achieve glycemic control. Expenditure for oral antidiabetic medicines in Bosnia and Herzegovina (B&H) is low accounting for only 2.53% of the total drug market expenditure...
September 2017: Materia Socio-medica
https://www.readbyqxmd.com/read/29109299/long-term-trends-in-antidiabetes-drug-usage-in-the-u-s-real-world-evidence-in-patients-newly-diagnosed-with-type-2-diabetes
#20
Olga Montvida, Jonathan Shaw, John J Atherton, Frances Stringer, Sanjoy K Paul
OJBECTIVE: To explore temporal trends in antidiabetes drug (ADD) prescribing and intensification patterns, along with glycemic levels and comorbidities, and possible benefits of novel ADDs in delaying the need for insulin initiation in patients diagnosed with type 2 diabetes. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes aged 18-80 years, who initiated any ADD, were selected (n = 1,023,340) from the U.S. Centricity Electronic Medical Records. Those who initiated second-line ADD after first-line metformin were identified (subcohort 1, n = 357,482); the third-line therapy choices were further explored...
November 6, 2017: Diabetes Care
keyword
keyword
118316
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"